OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process
  • Publisher Calendar

  • Products & Pricing
  • Banner Advertising Plans
  • eNewsletter Packages
  • Pre-Roll Advertising
  • Create A Deep Dive Conversation
  • Create a Video Release (VR)
  • Boost Earned Media Only $60

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5595
  • Acute Myelogenous Leukemia 226
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 562
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 209
  • Chronic Myelogenous Leukemia 54
  • Colorectal 172
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 177
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • Help 3
  • Hematologic Malignancies 206
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 179
  • Kidney 392
  • Liver 40
  • Lung 95
  • Lymphoma 235
  • Melanoma and Skin 107
  • Multiple Myeloma 535
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 554
  • Other 517
  • Ovarian 65
  • Pancreatic 104
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • Help
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Podcast Christopher Cann, MD @ChrisCannMD @VUMChealth @VUMC_Cancer #IASLC22 #SCLC  Circulating Tumor DNA Dynamics in Relapsed SCLC
0:08:06

Podcast Christopher Cann, MD @ChrisCannMD @VUMChealth @VU...

Christopher Cann, MD, Clinical Fellow, Division of Hematology/Oncology, Department of Medicine at Vanderbilt University Medical Center. In this video, he speaks about the IASLC 2022 Abstract - Circulating Tumor DNA Dynamics in Relapsed Small Cell Lung Cancer Are Predictive of Progression-Free and Overall Survival. 

Origins:

Relapsed small cell lung cancer (SCLC) is difficult to treat, with low overall survival and objective response rates (ORR) (OS). ORR is currently predicted to be 25-50 percent for platinum-sensitive illness and 10-20 percent for platinum-resistant disease, resulting in a short progression-free survival (PFS) of 4-5 months and an OS of less than one year from the onset of relapse. Because of this intrinsic chemoresistance, selecting the best cytotoxic chemotherapy regimen in this situation is extremely difficult. Individual patient chemosensitivity data can be collected in-vivo by assessing changes in circulating tumor DNA (ctDNA) levels following the initial dose of cytotoxic treatment, we reasoned.

Methodologies:

A plasma-based ctDNA assay developed previously was used to sequence 14 frequently mutated genes in SCLC (TP53, RB1, BRAF, KIT, NOTCH1-4, PIK3CA, PTEN, FGFR1, MYC, MYCL1, and MYCN) on 13 patients with relapsed SCLC who were eligible for additional systemic therapy (second (n = 6) or third-line (n = 7) therapy.

Rovalpituzumab tesirine (n=2), a checkpoint kinase 1 inhibitor (n=1), a platinum doublet (n=1), or paclitaxel (n=2) were used as second-line treatments. Rovalpituzumab tesirine (n=1), checkpoint kinase 1 inhibitor (n=1), irinotecan (n=1), or paclitaxel (n=4) were used as third-line treatments.

Each patient provided a pre-treatment ctDNA sample as well as at least one post-treatment sample. The difference in ctDNA peak variant allele frequency (VAF) between pre-treatment and first-on-treatment samples was calculated for each patient, and ORR, PFS, and OS were estimated.

Findings:

In our 13-patient sample, 5 (38%) had an objective response, with patients who had a larger than 0.1 percent rise in peak VAF at the initial on-treatment ctDNA measurement receiving no radiographic response to therapy (stable disease (n=2), disease progression (n=1). Notably, patients who had ctDNA clearance at the first on-treatment ctDNA assessment (n=3) had significantly longer median PFS and OS than those who had persisting signs of ctDNA (PFS: 170 days vs 85.5 days, OS: 337 days vs 123.5 days, respectively).

Outcome:

Early clearance of ctDNA predicts an improvement in PFS and OS in patients with recurrent SCLC, but an early increase in peak VAF indicated chemoresistance. Bigger cohorts are required to corroborate this discovery, and we are now gathering additional patients and samples for a larger study.

Lung
21 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Live

Upcoming Events

Spotlight Oncology News

Latest Videos

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD
0:05:37
Binimetinib: Combination Insights on the Treatment Strate...
3 Views
4 days Ago
Saranya Chumsri
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Geneoscopy: Efficacy of Non-Invasive Colorectal Cancer Screening Test Evaluated in the CRC-PREVENT Phase 3 Trial David Lieberman MD
0:09:22
Geneoscopy: Efficacy of Non-Invasive Colorectal Cancer Sc...
2 Views
5 days Ago
David Lieberman
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD
0:07:51
Adipocyte Vaccine: Presents Promising Results for Patient...
1 Views
5 days Ago
Nora Disis
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk
0:07:47
AI Risk Assessment: Sybil A Reliable Deep Learning Model ...
2 Views
5 days Ago
Florian Fitelmann
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - (951) 326-8827